Related Experiment Video
Updated: Oct 31, 2025
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
41.0K
Inhaled antibodies: Quality and performance considerations.
Anthony James Hickey1, Ian Edward Stewart1
1RTI International, Research Triangle Park, NC, USA.
Human Vaccines & Immunotherapeutics
|June 30, 2021
Summary
Antibody therapies show promise for lung diseases like asthma and infections, including COVID-19. Effective formulation and aerosol delivery are crucial for maintaining antibody integrity and therapeutic success.
Area of Science:
- Pulmonary Medicine
- Immunotherapy
- Drug Delivery
Background:
- Antibody therapy is gaining traction for lung diseases, spurred by COVID-19 research.
- Historically, antibodies targeted asthma hyper-reactivity and pulmonary infections.
- Protein therapeutics, like antibodies, present formulation and delivery challenges.
Purpose of the Study:
- To review challenges and opportunities in developing antibody therapeutics for lung diseases.
- To discuss quality and performance considerations for pulmonary drug delivery.
- To explore the use of nebulizers and dry powder inhalers for antibody administration.
Main Methods:
- Literature review of antibody therapy in pulmonary medicine.
- Analysis of formulation and aerosol delivery techniques for protein therapeutics.
- Examination of drug product development considerations.
Main Results:
- Antibody specificity requires careful attention to molecular integrity during formulation and delivery.
- Nebulizers and dry powder inhalers are viable delivery methods for protein therapeutics.
- Overcoming quality and performance barriers is key to successful antibody-based lung therapies.
Conclusions:
- Developing effective antibody treatments for lung diseases necessitates addressing formulation and delivery hurdles.
- Optimizing aerosol delivery systems is critical for maintaining antibody efficacy.
- Successful development hinges on matching delivery methods to specific drug and disease needs.
Related Concept Videos
01:23Inhaled Medications
500
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
500
01:30Asthma-IV: Diagnostic and Management
2.7K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.7K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.3K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.3K
01:17Drugs Used in Lower Respiratory Disorders: Overview
746
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
746
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.1K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.1K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.3K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.3K